Vivimed Labs (NSE:VIVIMEDLAB) Cyclically Adjusted Revenue per Share: ₹107.99 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:VIVIMEDLAB Vivimed Labs Ltd NSE:VIVIMEDLAB
34 GF Score
Price ₹5.04
GF Value ₹2.45
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Vivimed Labs Cyclically Adjusted Revenue per Share?

Vivimed Labs NSE:VIVIMEDLAB +1.20% 34 Cyclically Adjusted Revenue per Share is ₹107.99 as of Mar. 2026. GuruFocus rates NSE:VIVIMEDLAB with a GF Score™ of 34/100 and a GF Value™ of ₹2.45 (Significantly Overvalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Vivimed Labs's adjusted revenue per share for the three months ended in Mar. 2026 was ₹1.447. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹107.99 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Vivimed Labs's average Cyclically Adjusted Revenue Growth Rate was -15.90% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -14.00% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -10.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Vivimed Labs was -7.30% per year. The lowest was -14.00% per year. And the median was -10.90% per year.

As of today (2026-08-04), Vivimed Labs's current stock price is ₹5.04. Vivimed Labs's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was ₹107.99. Vivimed Labs's Cyclically Adjusted PS Ratio of today is 0.05.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Vivimed Labs was 0.21. The lowest was 0.03. And the median was 0.05.


Vivimed Labs  (NSE:VIVIMEDLAB) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Vivimed Labs's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=5.04/107.99
=0.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Vivimed Labs was 0.21. The lowest was 0.03. And the median was 0.05.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Vivimed Labs Cyclically Adjusted Revenue per Share Related Terms


Vivimed Labs Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Vivimed Labs's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vivimed Labs Cyclically Adjusted Revenue per Share Chart

Vivimed Labs Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 181.65 167.44 151.38 129.21 107.99

Vivimed Labs Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 129.21 124.66 120.18 113.87 107.99

NSE:VIVIMEDLAB vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Vivimed Labs's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vivimed Labs Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vivimed Labs's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Vivimed Labs's Cyclically Adjusted PS Ratio falls into.


NSE:VIVIMEDLAB
34GF Score
Vivimed Labs Ltd NSE:VIVIMEDLAB
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vivimed Labs Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Vivimed Labs's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=1.447/164.2724*164.2724
=1.447

Current CPI (Mar. 2026) = 164.2724.

Vivimed Labs Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 43.971 105.961 68.169
201609 35.779 105.961 55.468
201612 43.100 105.196 67.304
201703 52.287 105.196 81.651
201706 38.043 107.109 58.346
201709 34.457 109.021 51.919
201712 35.808 109.404 53.767
201803 28.393 109.786 42.484
201806 41.705 111.317 61.545
201809 42.291 115.142 60.336
201812 28.348 115.142 40.444
201903 34.547 118.202 48.012
201906 40.363 120.880 54.852
201909 33.917 123.175 45.233
201912 23.856 126.235 31.044
202003 17.731 124.705 23.357
202006 37.718 127.000 48.787
202009 26.702 130.118 33.711
202012 33.544 130.889 42.099
202103 4.698 131.771 5.857
202106 7.824 134.084 9.586
202109 6.558 135.847 7.930
202112 6.817 138.161 8.105
202203 7.286 138.822 8.622
202206 6.048 142.347 6.980
202209 5.340 144.661 6.064
202212 6.727 145.763 7.581
202303 3.990 146.865 4.463
202306 4.267 150.280 4.664
202309 4.061 151.492 4.404
202312 5.012 152.924 5.384
202403 4.148 153.035 4.453
202406 3.545 155.789 3.738
202409 2.987 157.882 3.108
202412 4.400 158.323 4.565
202503 3.110 157.552 3.243
202506 2.570 159.755 2.643
202509 2.484 162.289 2.514
202512 1.932 163.281 1.944
202603 1.447 164.272 1.447

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹107.99 mean?
Vivimed Labs (NSE:VIVIMEDLAB) has a Cyclically Adjusted Revenue per Share of ₹107.99 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Vivimed Labs and its competitors.
Is Vivimed Labs' Cyclically Adjusted Revenue per Share too high?
Vivimed Labs' current Cyclically Adjusted Revenue per Share is ₹107.99. Overall, Vivimed Labs has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vivimed Labs' Cyclically Adjusted Revenue per Share compare to ZTS?
Vivimed Labs' Cyclically Adjusted Revenue per Share of ₹107.99 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Vivimed Labs and its competitors. Vivimed Labs's current Cyclically Adjusted Revenue per Share is ₹107.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivimed Labs stock overvalued right now?
Based on GuruFocus' analysis, Vivimed Labs (NSE:VIVIMEDLAB) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹2.45, compared to a current price of ₹5.04 — trading 105.7% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹107.99. Vivimed Labs' overall GF Score™ is 34/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Vivimed Labs (NSE:VIVIMEDLAB), the current Cyclically Adjusted Revenue per Share is ₹107.99 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vivimed Labs (NSE:VIVIMEDLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Vivimed Labs stock appears to be overvalued. The current stock price of ₹5.04 is trading 105.7% above its estimated GF Value™ of ₹2.45. GuruFocus considers Vivimed Labs to be Significantly Overvalued.

Key valuation signals for NSE:VIVIMEDLAB:

  • Cyclically Adjusted Revenue per Share: ₹107.99
  • GF Value™: ₹2.45 vs. price of ₹5.04 (105.7% above fair value)
  • GF Score™: 34/100 with 6 warning signs

No single metric tells the full story. See the NSE:VIVIMEDLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Vivimed Labs Business Description

Other Exchanges 532660:India
Address Green Lands, Beside The Plaza Hotel, D.No. 6-3-866/1/G1, 3rd & 4th Floor, GMR Towers, Begumpet, Hyderabad, TG, IND, 500016
Vivimed Labs Ltd is an India-based company that is engaged in the Business of Active pharmaceutical ingredients, Intermediates, Nutraceutical ingredients, CDMO Finished Dosage Formulation, Specialty Chemicals, and Retail Branded Formulation manufacturing. The company has three reportable segments: the Speciality Chemicals Business, the Pharma Business, and others. The majority of revenue is earned through the Pharma business.
34GF Score

Get the complete analysis for NSE:VIVIMEDLAB

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹5.04
Price
₹2.45
GF Value